Thursday 16 October, 2025
Introduction: Pentaglobin® is a polyclonal intravenous immunoglobulin preparation consisting of 12% immunoglobulin M (IgM), 12% immunoglobulin A (IgA), and 76%…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
PBPK modelling of the DDI between a Drug X and gemfibrozil
Thursday 16 October, 2025
Objectives: A PBPK model for drug X and its active metabolite was built in Simcyp V20. The parent drug was…
Read moreSwitching from immediate release to modified release can have an impact on intestinal drug-drug interactions: A PBPK simulation study using oxybutynin as a case example
Thursday 16 October, 2025
Objectives: A recently published absorption physiologically-based pharmacokinetic (PBPK) model was used and applied to mechanistically predict the oral bioavailability differences observed…
Read moreA physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol and caffeine
Thursday 16 October, 2025
Objectives: Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure….
Read moreNovel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption
Thursday 16 October, 2025
Objectives: In vitro-in vivo correlation (IVIVC) is a predictive mathematical approach to establish a relationship between an in vitro dissolution…
Read moreUse of modeling and simulation methods to support the generic application of a vaginal delivery system
Thursday 16 October, 2025
Introduction: A pharmaceutical company developed a generic contraceptive vaginal delivery system containing etonogestrel (ENG, 0.120 mg/day) and ethinyl estradiol (EE,…
Read moreOn the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients
Thursday 16 October, 2025
Objectives: To develop a population pharmacokinetic (PK) model for describing the absorption kinetics and enterohepatic recirculation (EHC) of formoterol (FOR)…
Read moreModel-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human
Thursday 16 October, 2025
Objectives: To predict the enterohepatic circulation of total bile acids (BA) from their plasma concentrations in relation to fat intake. Methods: Data…
Read moreDevelopment of a whole body physiologically-based pharmacokinetic (PBPK) model for inhaled salmeterol to predict interactions with CYP3A4 inhibitors
Thursday 16 October, 2025
Objectives: To develop a whole body PBPK model for salmeterol, capable of describing the pharmacokinetics (PK) of salmeterol following inhalation…
Read moreCell-level based tumor cPBPK model to study mAb distribution within solid tumors and implications for efficacious treatment
Thursday 16 October, 2025
Objectives: Heterogeneous distribution of antibodies within tumor tissue, often discussed in the context of the `binding site barrier’, is still…
Read more